CD44 and breast cancer: In a breast cancer study, CTC subsets were selected for EpCAM negativity, positivity for stem cell markers (CD44+/CD24−) and combinatorial expression of uPAR/intβ1 because downregulation of these two markers has been directly implicated in breast cancer dormancy (90).